Frankfurt
27.06.25 | 08:07
0,190 Euro
-32,80 % -0,093
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.06. | AlzeCure Pharma: AlzeCure Receives an Additional Subscription Commitment of Approximately SEK 5 million in the Upcoming Rights Issue | 241 | ACCESS Newswire | NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, WITHIN OR INTO THE RUSSIAN FEDERATION, BELARUS, AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND... ► Artikel lesen | |
| 16.06. | Notice To Extraordinary General Meeting In Alzecure Pharma AB | 216 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / June 16, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - The shareholders of AlzeCure Pharma AB are hereby summoned to an extraordinary general meeting to be held on... ► Artikel lesen | |
| 16.06. | AlzeCure Pharma: AlzeCure Carries out a Rights Issue of Approximately SEK 48.5 million | 276 | ACCESS Newswire | NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, WITHIN OR INTO THE RUSSIAN FEDERATION, BELARUS, AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND... ► Artikel lesen | |
| 12.06. | AlzeCure Pharma: AlzeCure receives positive FDA response regarding Phase II/III studies with ACD440 in a rare disease | 317 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / June 12, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 04.06. | AlzeCure Pharma to present at Redeye Investor Forum on June 11 | 243 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / June 4, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 03.06. | AlzeCure Pharma to Present at Stora Aktiedagarna in Stockholm on June 10 | 283 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / June 3, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 14.05. | Communiqué from the Annual General Meeting of AlzeCure Pharma on 14 May 2025 | 316 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / May 14, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - Today, 14 May 2025, the annual general meeting was held in AlzeCure Pharma AB (publ) (the "Company"). Below is... ► Artikel lesen | |
| ALZECURE PHARMA Aktie jetzt für 0€ handeln | |||||
| 05.05. | AlzeCure Pharma: AlzeCure Publishes its Interim Report for January - March 2025 | 335 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / May 5, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO: ALZCUR) today announced that its interim report for the period January - March... ► Artikel lesen | |
| 05.05. | AlzeCure Pharma AB: AlzeCure publishes its interim report for January - March 2025 | 192 | GlobeNewswire (Europe) | AlzeCure Pharma AB (publ) (FN STO: ALZCUR) today announced that its interim report for the period January - March 2025 is now available on the company's website: www.alzecurepharma.com/en/section/investors/financial-reports/
"The... ► Artikel lesen | |
| 09.04. | Notice to Annual General Meeting in AlzeCure Pharma AB | 385 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / April 9, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - The shareholders of AlzeCure Pharma AB, reg. no. 559094-8302 (the "Company") are hereby invited to attend the... ► Artikel lesen | |
| 07.04. | AlzeCure Pharma: New Data Bolstering the Anti-inflammatory Effect of NeuroRestore ACD856 Presented at Alzheimer's Conference | 383 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / April 7, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 03.04. | AlzeCure Pharma publishes its Annual Report for 2024 | 358 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / April 3, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 02.04. | AlzeCure Pharma: New Scientific Article in Nature Linking the Potential use of NeuroRestore ACD856 for the Treament of Obesity | 390 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / April 2, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 01.04. | AlzeCure Pharma to present at Redeye Theme: Alzheimer & Parkinsons on April 8 | 338 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / April 1, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 27.02. | AlzeCure Pharma: AlzeCure Publishes its Year-End Report for January - December 2024 | 780 | ACCESS Newswire | STOCKHOLM, SWEDEN / ACCESS Newswire / February 27, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its Year-end report for the period January... ► Artikel lesen | |
| 24.02. | AlzeCure Pharma: New Article Showing the Unique Mechanism of Action Behind Alzstatin as an Alzheimer's Treatment | 434 | ACCESS Newswire | STOCKHOLM, SWEDEN / ACCESS Newswire / February 24, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR) ), a pharmaceutical company that develops candidate drugs for... ► Artikel lesen | |
| 17.02. | AlzeCure Pharma: AlzeCure Receives EU Grant for Phase 2 Clinical Trial of NeuroRestore ACD856 for Alzheimer's Disease | 420 | ACCESS Newswire | STOCKHOLM, SWEDEN / ACCESS Newswire / February 17, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for... ► Artikel lesen | |
| 21.01. | AlzeCure Pharma: AlzeCure Receives Abstract Acceptance at Alzheimer's Congress AD/PD 2025 on NeuroRestore ACD856 | 459 | ACCESS Newswire | STOCKHOLM, SE / ACCESSWIRE / January 21, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 27.11.24 | AlzeCure Pharma: AlzeCure to Present at the Pharma Outsourcing Conference in Stockholm | 450 | ACCESS Newswire | STOCKHOLM, SWEDEN / ACCESSWIRE / November 27, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops small molecule drugs for... ► Artikel lesen | |
| 26.11.24 | AlzeCure Pharma to Present at Redeye Life Science Day on December 3 | 422 | ACCESS Newswire | STOCKHOLM, SWEDEN / ACCESSWIRE / November 26, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VERTEX PHARMACEUTICALS | 378,70 | +0,49 % | Vertex Pharmaceuticals Incorporated (VRTX) Benefited from the Launch of its New Drug | ||
| VIATRIS | 7,772 | +0,54 % | Viatris Reports Positive Data From Presbyopia Study | WASHINGTON (dpa-AFX) - Viatris Inc. (VTRS), Thursday announced positive top-line results from VEGA-3, evaluating MR-141 in patients with presbyopia, the progressive loss of the ability to focus... ► Artikel lesen | |
| OPKO HEALTH | 1,114 | -1,59 % | OPKO Health, Inc.: OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting | MIAMI and JERUSALEM, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX) ("Entera") today announced that new pharmacologic and pharmacokinetic in vivo... ► Artikel lesen | |
| ALTIMMUNE | 2,951 | -0,87 % | Altimmune, Inc: Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH | First product candidate to demonstrate significant MASH effects and weight loss at 24 weeks Trial met its primary endpoint with statistically significant MASH resolution without worsening of fibrosis... ► Artikel lesen | |
| JAGUAR HEALTH | 2,500 | -7,75 % | Jaguar Health, Inc.: Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset | Strategic decision positions Jaguar to diversify treasury holdings with a long-term digital store of value SAN FRANCISCO, CA / ACCESS Newswire / June 26, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar"... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 1,768 | +6,89 % | SELLAS Life Sciences wird in Russell 3000 und Russell 2000 Indizes aufgenommen | ||
| AURINIA PHARMACEUTICALS | 7,306 | -0,84 % | Aurinia Pharmaceuticals Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| KIORA PHARMACEUTICALS | 3,000 | -1,32 % | Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in Asia | Total potential deal value of $110 million plus royaltiesKiora to receive an immediate $1.25 million exclusive option feeIf the option is exercised, Kiora will receive an additional mid-single digit... ► Artikel lesen | |
| LIPOCINE | 3,200 | -0,93 % | Lipocine Inc.: Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression | Phase 3 Top Line Results Expected Q2 2026
SALT LAKE CITY, June 26, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging... ► Artikel lesen | |
| PHOTOCURE | 4,480 | +3,11 % | Photocure ASA - Share option grant | ||
| ACLARIS THERAPEUTICS | 1,240 | +0,45 % | Aclaris Therapeutics initiates Phase 1 trial for ATI-052 antibody | ||
| EUROBIO SCIENTIFIC | 25,100 | +0,40 % | Eurobio Scientific: EB Development rises above 90% threshold | EB Development rises above 90% threshold Paris, May 19, 2024 - 7:00 pm - Eurobio Scientific (FR0013240934, ALERS, PEA-PME eligible), a leading French group in in vitro medical diagnostics and life... ► Artikel lesen | |
| MEDICURE | 0,760 | -0,65 % | Medicure, Inc.: Medicure Announces Closing of Purchase Agreement for The Acquisition of West Olympia Pharmacy | WINNIPEG, MB / ACCESS Newswire / June 17, 2025 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals... ► Artikel lesen | |
| BAYER | 26,975 | +2,64 % | EQS-PVR: Bayer Aktiengesellschaft: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: Bayer Aktiengesellschaft
Bayer Aktiengesellschaft: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
23.06.2025... ► Artikel lesen | |
| MERCK KGAA | 112,65 | +0,90 % | MilliporeSigma and "Abbott Elementary" Inspire Students' Curiosity With Hands-On STEM | NORTHAMPTON, MA / ACCESS Newswire / June 25, 2025 / Between September 2024 and April 2025, MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, teamed up with... ► Artikel lesen |
ALZECURE PHARMA AB gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell -32,80 % bei einem Aktienkurs von 0,190 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALZECURE PHARMA AB finden Sie auf Wallstreet Online.